Lubris BioPharma
PrivateCompany Overview
Lubris BioPharma is a biopharmaceutical company that develops a recombinant human protein, lubricin, for the treatment of dry eye, osteoarthritis, and other inflammation-related conditions.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Lubris BioPharma Comparables
Compare Lubris BioPharma with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| TearSolutions | 80% | |
| Novartis | 78% | |
| Stuart Therapeutics, Inc. | 78% | |
Lubris BioPharma Funding Rounds
Historical fundraising activity
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 3, 2026
Monthly visitors increased 46% MoM.
- Jan 6, 2026
Monthly visitors increased 34% MoM.
Lubris BioPharma Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Lubris BioPharma's valuation, stock price, and market status.